BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30611847)

  • 1. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
    Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors.
    Kleinschek A; Meyners C; Digiorgio E; Brancolini C; Meyer-Almes FJ
    ChemMedChem; 2016 Dec; 11(23):2598-2606. PubMed ID: 27860422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
    Wolff B; Jänsch N; Sugiarto WO; Frühschulz S; Lang M; Altintas R; Oehme I; Meyer-Almes FJ
    Eur J Med Chem; 2019 Dec; 184():111756. PubMed ID: 31630054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
    Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
    J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
    Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
    Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8.
    Kulandaivelu U; Chilakamari LM; Jadav SS; Rao TR; Jayaveera KN; Shireesha B; Hauser AT; Senger J; Marek M; Romier C; Jung M; Jayaprakash V
    Bioorg Chem; 2014 Dec; 57():116-120. PubMed ID: 25462986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetically selective and potent inhibitors of HDAC8.
    Schweipert M; Jänsch N; Sugiarto WO; Meyer-Almes FJ
    Biol Chem; 2019 May; 400(6):733-743. PubMed ID: 30521473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8.
    Decroos C; Clausen DJ; Haines BE; Wiest O; Williams RM; Christianson DW
    Biochemistry; 2015 Mar; 54(12):2126-35. PubMed ID: 25793284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
    Hassan MM; Israelian J; Nawar N; Ganda G; Manaswiyoungkul P; Raouf YS; Armstrong D; Sedighi A; Olaoye OO; Erdogan F; Cabral AD; Angeles F; Altintas R; de Araujo ED; Gunning PT
    J Med Chem; 2020 Aug; 63(15):8634-8648. PubMed ID: 32672458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
    Adhikari N; Amin SA; Jha T
    Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
    Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
    Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
    Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
    Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and structural characterization of HDAC8 mutants associated with Cornelia de Lange syndrome spectrum disorders.
    Decroos C; Christianson NH; Gullett LE; Bowman CM; Christianson KE; Deardorff MA; Christianson DW
    Biochemistry; 2015 Oct; 54(42):6501-13. PubMed ID: 26463496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit.
    Greenwood SOR; Chan AWE; Hansen DF; Marson CM
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126926. PubMed ID: 31952961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.